Skip to main content
Clinical Trials/NCT01795690
NCT01795690
Completed
Not Applicable

Clinical Registry Describing Treatment Reality of Patients With Cancer-(Therapy)-Induced Anemia

iOMEDICO AG1 site in 1 country1,018 target enrollmentDecember 2011
ConditionsAnemia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Anemia
Sponsor
iOMEDICO AG
Enrollment
1018
Locations
1
Primary Endpoint
Documentation of therapies
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

The purpose of this registry is to record information of routine treatment of anemia in cancer patients in Germany. An overview of the current treatment of anemia in German outpatient centers and hospitals will be provided. Primary outcome parameters, e.g. improvement in hemoglobin levels and changes in QoL, as well as patient characteristics of different treatments will be analyzed.

Registry
clinicaltrials.gov
Start Date
December 2011
End Date
February 2016
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Histologically confirmed malignant disease
  • Hemoglobin level \< 11 g/dl (female) or \< 12 g/dl (male)
  • Start of antianemic therapy no more than 7 days prior to informed consent
  • Performance status 0 - 3 (Karnofsky-Index \>= 40%)
  • Minimum age: 18 years
  • Informed written consent

Exclusion Criteria

  • Hypersensitivity against antianemic therapies
  • Myelodysplastic Syndrome
  • Experimental antianemic therapy

Outcomes

Primary Outcomes

Documentation of therapies

Time Frame: 12 weeks per patient

Overview on the current routine treatment of anemia in cancer patients in Germany

Secondary Outcomes

  • Change in hemoglobin levels and QoL(12 weeks per patient)

Study Sites (1)

Loading locations...

Similar Trials